Company intelligence / Profile preview

Peptimmune

Cambridge, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 1

Overview

Peptimmune completed Phase Ib studies of PI-2301 in secondary progressive multiple sclerosis and conducted a Phase I trial of PI-0824 in pemphigus vulgaris. The company also licensed an anti-obesity product from Genzyme that reached early clinical development. Despite some positive results, the company filed for Chapter 7 bankruptcy in 2011 after failing to secure further funding.

Therapeutic areas: NeurologyDermatologyMetabolic Disorders
Modalities: Peptide copolymersbiologics
Industry: Biotech

Drug pipeline

2 assets

desmoglein 3 synthetic peptide

1 more asset in the full pipeline.

Request access →

Partnerships

Genzyme Corp. (licensed anti-obesity product)

Beyond the preview

Go deeper on Peptimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptimmune.

Explore the full profile